PMID: 3279907Jan 1, 1988Paper

Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers

Antimicrobial Agents and Chemotherapy
M BoeckhP Koeppe

Abstract

The pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime were investigated in 10 healthy volunteers. The pharmacokinetic parameters showed no significant differences (P less than 0.05) between single and combined administration. No antagonistic effects were observed in serum bactericidal activity with the combination against 20 gram-positive and 20 gram-negative locally isolated bacteria. A titer of greater than or equal to 1:8 was generated by the combination against all test strains except enterococci. Seven of ten volunteers developed a typical "red man's syndrome" during the administration of 1.0 g of vancomycin.

References

Jan 1, 1979·Therapeutic Drug Monitoring·J R Uhl, J P Anhalt
Nov 6, 1975·The New England Journal of Medicine·D J Greenblatt, J Koch-Weser
Jan 24, 1985·The New England Journal of Medicine·F BoagP Dandona
May 1, 1985·Annals of Internal Medicine·B H Ackerman, R W Bradsher
Mar 1, 1987·Antimicrobial Agents and Chemotherapy·D P HealyT J Comstock
Jul 1, 1985·Infection·C Simon, G Littschwager
Sep 19, 1985·The New England Journal of Medicine·A K Pau, R Khakoo
Feb 1, 1974·The Journal of Infectious Diseases·J KlasterskyD Weerts
Mar 1, 1981·Annals of Internal Medicine·R C MoelleringD J Greenblatt
Jan 1, 1983·Antimicrobial Agents and Chemotherapy·B F Farber, R C Moellering
Sep 1, 1983·Antimicrobial Agents and Chemotherapy·B KemmerichH Knothe
Mar 1, 1983·The Journal of Infectious Diseases·M S ReitzR C Gallo
Jan 1, 1983·Therapeutic Drug Monitoring·K S SchwenzerJ P Anhalt
Jan 1, 1984·Antimicrobial Agents and Chemotherapy·H LodeK Borner
Apr 1, 1984·Antimicrobial Agents and Chemotherapy·G R MatzkeW F Keane
Apr 1, 1983·Antimicrobial Agents and Chemotherapy·N BrownG P Bodey
Sep 10, 1982·Journal of Chromatography·J B McClainS Brown
Sep 1, 1982·Antimicrobial Agents and Chemotherapy·J C RotschaferL D Solem
Dec 1, 1980·Computer Programs in Biomedicine·P Koeppe, C Hamann
Nov 1, 1981·Reviews of Infectious Diseases·B A CunhaC H Nightingale
Apr 1, 1980·Journal of Clinical Pharmacology·D J KrogstadD J Greenblatt

Citations

Feb 24, 2011·Nature Reviews. Nephrology·Rachel F EylerMedscape
Oct 3, 1999·Critical Care Medicine·C L RenzJ Moss
Apr 1, 1990·Antimicrobial Agents and Chemotherapy·D P HealyR Polk
May 1, 1990·Antimicrobial Agents and Chemotherapy·J SahaiR Polk
Jun 1, 1990·Antimicrobial Agents and Chemotherapy·A K HurstE C Harrison
Sep 1, 1993·Antimicrobial Agents and Chemotherapy·W PaulfeuerbornH Lode
Jul 1, 2015·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Chien-Chih WuFe-Lin Lin Wu
Oct 1, 1992·Burns : Journal of the International Society for Burn Injuries·T L Rice
Dec 31, 2003·Journal of Clinical Apheresis·Polly E KintzelKarim Anton Calis
Feb 16, 2018·CPT: Pharmacometrics & Systems Pharmacology·Chie EmotoTsuyoshi Fukuda
Jan 15, 2018·Clinical Pharmacokinetics·Valentin Al Jalali, Markus Zeitlinger
Sep 18, 2020·International Journal of Antimicrobial Agents·Suzanne L ParkerJason A Roberts

Related Concepts

Fortum
Drug Combinations
Intravenous Infusion Procedures
AB-Vancomycin

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.